What Is ePRO?

ePRO, or electronic patient-reported outcomes, is the digital collection of information reported directly by patients about their symptoms, functioning, and quality of life during a clinical trial. Patients complete assessments on a smartphone, tablet, or web browser, and the data flows to the study team in real time.

What makes ePRO distinct is the source of the data. It comes straight from the patient, with no clinician or site staff member interpreting or filtering it along the way. That directness is what makes it so valuable to sponsors: it captures the trial experience as the person living it perceives it, not as someone else describes it on their behalf.

Because of this, ePRO has become one of the most widely used tools for gathering patient-centered evidence, and as ePRO software has matured, it’s also become far easier for study teams to configure and monitor.

How Does ePRO Work?

An ePRO deployment generally moves through three stages:

1. Setup: The study team builds the assessments and defines a completion schedule, then onboards patients on their own device (BYOD) or one provisioned by the study.
2. Participation: Patients receive prompts by push notification, email, or text, and complete assessments at home, in clinic, or on the go. Responses are submitted immediately into the study database.
3. Monitoring: Predefined conditions trigger alerts to site staff when a response warrants follow-up, while study teams track completion rates and adherence in real time.

Across the stages, ePRO can capture a wide range of information: physical symptoms, treatment side effects, functional limitations, emotional well-being, and overall quality of life.

ePRO vs. eCOA: What’s the Difference?

ePRO is a subset of eCOA, not a competing approach, as every ePRO assessment is an eCOA, but not every eCOA is an ePRO. eCOA, or electronic clinical outcome assessment, is the umbrella term covering all electronically captured outcome data in a trial, regardless of who provides it. ePRO sits inside that umbrella as the category reported exclusively by the patient.

The eCOA family

Every ePRO is an eCOA — but not every eCOA is an ePRO

eCOA is the umbrella term for all electronically captured outcome data in a trial. What separates the four types is simply who provides the data.

eCOA — electronic clinical outcome assessment

• ePRO

  Patient-reported

  Reported by the patient, with no clinician interpreting it along the way.

  Symptom diaries, side effects, quality-of-life questionnaires

• eClinRO

  Clinician-reported

  Completed by a clinician applying professional judgment.

  Clinical severity ratings and investigator assessments

• eObsRO

  Observer-reported

  Completed by a caregiver or other observer, not the patient.

  A parent logging a child’s symptoms

• ePerfO

  Performance-based

  Generated by a standardized task the patient performs.

  A timed walk test or memory task

Use ePRO alone when the patient’s own experience is the primary endpoint, or combine it with the other types when multiple perspectives add value.

The other three types fill in the picture from different vantage points. 

• eClinRO is completed by a clinician applying professional judgment;
• eObsRO is completed by a caregiver or observer;
• ePerfO comes from a standardized task the patient performs, such as a walk test. 

A study might use ePRO alone when the patient’s own experience is the primary endpoint, or combine it with the other eCOA types when multiple perspectives add value.

ePRO vs. Paper-Based Patient Diaries

Paper diaries have long been used to collect patient-reported information, but they create practical challenges for both participants and study teams. ePRO moves the same basic concept into a digital environment while adding features that improve visibility and data handling.

Side-by-side comparison

ePRO vs. paper-based patient diaries

Four practical differences that affect participants, site staff, and the data researchers ultimately rely on.

Comparison of paper diaries and ePRO across timing and recall, in-trial visibility, data quality and safety response, and missing data.

Factor	Paper diaries	ePRO
Timing and recall	Can be filled in from memory just before a visit, well after the events they record.	Every entry is timestamped as it’s submitted, so data reflects the moment it was reported.
Visibility during the trial	Compliance stays a mystery until the diary is physically returned.	Adherence is visible in real time, so gaps can be addressed while the study is still running.
Data quality and safety response	Requires manual transcription into the study database, introducing errors and delays.	Data enters directly with validation at the point of entry, and can alert site staff immediately when a response signals a safety concern.
Missing data	Gaps may only become apparent afterward, likely once an issue arises.	Digital reminders encourage participants to complete assessments when they are due.

• Timing and recall. Paper diaries can be filled in from memory just before a visit, well after the events they’re meant to record. ePRO timestamps every entry as it’s submitted, so the data reflects the moment it was reported rather than a reconstruction of it.
• Visibility during the trial. With paper, compliance is a mystery until the diary is physically returned. ePRO makes adherence visible in real time, so gaps can be addressed while the study is still running instead of discovered after the fact.
• Data quality and safety response. Paper entries require manual transcription into the study database, which introduces errors and delays. ePRO enters data directly, with validation built into the point of entry, and it can alert site staff immediately when a response signals a safety concern.
• Missing data. Paper gaps may only become apparent afterward, likely once an issue arises. Digital reminders can encourage participants to complete assessments when they are due.

Collectively, these differences make ePRO more than a digital replacement for paper diaries. By capturing patient-reported data closer to the moment it happens, making adherence visible as the study progresses, and reducing manual data handling, ePRO can improve both the participant experience and the quality of the data researchers rely on.

Benefits of ePRO in Clinical Trials

These advantages over paper add up to real, measurable benefits once ePRO is deployed across a study. Here’s where those gains show up most: 

Higher-Quality, More Accurate Data

One of the biggest advantages of ePRO is that it creates a more direct path between the participant and the study database. 

Timestamped entries can reduce the likelihood of backfilling that’s long been associated with paper diaries, as they reduce the opportunity for participants to reconstruct several days of information from memory. On the other hand, direct entry into the database removes the errors and duplication that come with manual transcription, strengthening the reliability of the data collected across the study.

This matters because clinical trial data needs to be reliable, traceable, and fit for its intended purpose. ICH E6(R3), for example, emphasizes data integrity and describes important characteristics such as being attributable, legible, contemporaneous, original, accurate, complete, secure, and reliable.

Real-Time Visibility and Faster Response

Traditional data collection often means waiting for information to reach the site before it can be reviewed. ePRO can shorten that gap.

Study teams can see submissions the moment they arrive rather than waiting for the next scheduled visit. Automated alerts can also flag responses that do not meet predefined criteria, allowing appropriate site personnel to determine whether follow-up is needed. Faster awareness of potential adverse events supports both patient safety and protocol adherence, making real-time reporting one of the strongest arguments for moving away from visit-based data collection.

Improved Patient Compliance and Retention

Clinical trial participation can involve frequent questionnaires, appointments, and other study activities. With the help of digital assessments, though, clinicians can encourage participation due to the convenience. Reminders and familiar mobile interfaces make it easier for patients to fit assessments into daily life rather than treating them as a separate chore.

Continuous adherence monitoring also means study teams can identify patterns of missed assessments rather than discovering a problem much later. Reducing unnecessary participation burden can be particularly useful in longer studies, where maintaining engagement over time can be challenging.

Reduced Site Burden

ePRO can also reduce repetitive administrative work for research sites. Instead of collecting paper diaries and manually transferring responses into a clinical database, electronic systems can capture the information digitally from the start. When it connects directly into an EDC system, it also cuts down on source data verification, freeing site staff to focus on participant care instead of data entry.

Support for Decentralized and Hybrid Studies

ePRO can be especially useful for decentralized and hybrid clinical trials because participants do not necessarily need to visit a research site every time they need to provide information. When ePRO connects with an electronic data capture (EDC) environment, the flow of information can become more streamlined and reduce the need for separate reconciliation processes. The result is less time spent on manual data handling and more time for site staff to focus on participant-facing responsibilities.

BYOD vs. Provisioned Devices

When implementing ePRO, one practical question is how patients will access the assessments. With BYOD, participants use their own smartphone or tablet. This can reduce device costs, simplify logistics, and allow patients to use technology they already know. The trade-off is that the ePRO system needs to support a broad range of devices and operating systems.

With provisioned devices, the study supplies participants with a smartphone or tablet. This gives the sponsor greater control over the hardware and software environment and can help accommodate participants who do not have a compatible personal device. However, purchasing, configuring, shipping, replacing, and retrieving devices adds cost and logistical work.

A hybrid approach can combine both models. The right choice depends on the study population, protocol requirements, budget, geographic reach, and accessibility needs. Broad device support can also help make BYOD more practical across different participant groups.

ePRO and Regulatory Compliance

Using ePRO does not remove the regulatory responsibilities that apply to clinical trial data. Electronic records need appropriate controls to ensure they are trustworthy, reliable, and traceable. In the United States, 21 CFR Part 11 establishes requirements relevant to electronic records and electronic signatures. In addition, CROs in the United States must follow the FDA guidance on system validation, audit trails, records retention, and controls over electronic records. More recent FDA guidance also emphasizes selecting and developing clinical outcome assessments that are a fit for purpose.

Digital data is also held accountable through the ICH E6(R3) Good Clinical Practice guideline, which emphasizes data integrity and appropriate controls for computerized systems. 

Alongside data integrity and regulation is the preservation of privacy. Depending on the study and where participants are located, requirements may include HIPAA in the United States and GDPR in the European Union. HIPAA establishes protections for protected health information, while the GDPR treats health data as a specially protected category of personal data. In practice, controls such as audit trails, timestamps, role-based access, authentication, validation, and secure data handling help support these requirements.

What to Look for in ePRO Software

When evaluating ePRO software in clinical trials, a few questions tend to matter most:

• Flexibility and integration: Does it support BYOD across iOS and Android as well as provisioned devices, and does the data flow directly into EDC or require manual reconciliation?
• Real-time capability and configurability: Can the system alert site staff based on predefined response conditions, and can study teams build or amend assessments themselves without waiting on vendor change orders?
• Compliance, accessibility, and reporting: Does the vendor provide validation documentation and Part 11 support, does the platform accommodate multiple languages and assistive technology, and can teams monitor adherence and outcome trends as the study progresses?

Reporting is particularly important because collecting data is only part of the process. Teams also need practical ways to understand what the data is showing.

TrialKit ePRO: Patient-Reported Data in a Unified Platform

TrialKit brings ePRO and eCOA into a single eClinical platform where patient-reported data connects directly to EDC and eSource without a separate reconciliation step. That means native mobile support for iOS and Android, BYOD, and device handoff workflows. 

It also means integration with wearables and web apps, automated notifications when a response signals a potential adverse event, and real-time adherence monitoring. For sponsors weighing how to bring patient-reported data into their trial, having it built into the same platform as EDC removes one more point of friction between collecting data and acting on it.

FAQs About ePRO

What is ePRO in clinical trials?

ePRO, or electronic patient-reported outcomes, is the digital collection of information reported directly by trial participants about their symptoms, treatment side effects, physical functioning, and quality of life. Patients complete assessments on a smartphone, tablet, or web browser according to a schedule defined by a protocol, and responses are submitted electronically to the study team. The defining feature of ePRO is that the data comes straight from the patient, without interpretation by site staff.

What is the difference between ePRO and eCOA?

ePRO is a subset of eCOA rather than an alternative to it. eCOA, or electronic clinical outcome assessment, is the umbrella term for all electronic outcome data collected in a trial, including clinician-reported (eClinRO), observer-reported (eObsRO), and performance-based (ePerfO) assessments. ePRO is the category within eCOA that captures the patient’s own perspective. Every ePRO assessment is a form of eCOA, but eCOA also includes data reported by people other than the patient.

Why is ePRO important?

Patient-reported outcomes capture information that clinical measurements alone cannot show, including how a treatment affects daily functioning, symptom burden, and overall well-being. Regulatory agencies increasingly value this data because it reflects the patient experience directly. Collecting it electronically adds accuracy through timestamping, reduces recall bias, and gives study teams real-time visibility into how participants are doing between visits.

How is ePRO data collected?

Patients receive prompts on a schedule set by the protocol, delivered through push notifications, email, or text message. They complete the assigned questionnaire on a smartphone, tablet, or web browser and submit their responses, which enter the study database immediately. Depending on the study design, patients may use their own device under a BYOD approach or a device provisioned by the study.

Does ePRO improve data quality compared to paper diaries?

Yes, primarily because ePRO records when each entry was actually made. Paper diaries are vulnerable to backfilling, where a participant completes several days of entries shortly before a site visit, which introduces recall bias and undermines the timing assumptions built into the analysis. ePRO timestamps every submission, sends reminders that reduce missed entries, and eliminates the transcription step required to move paper responses into the database.

Can patients use their own devices for ePRO?

Yes. Bring-your-own-device (BYOD) approaches let participants complete assessments on their own smartphone or tablet, which lowers study costs, shortens onboarding, and lets patients use an interface they already know. BYOD requires ePRO software with broad compatibility across operating systems and screen sizes. Some studies provide devices instead, either to guarantee uniformity or to support participants who lack a suitable device of their own.

Is ePRO data subject to regulatory requirements?

Yes. ePRO systems used in regulated research must meet electronic records and signature requirements such as 21 CFR Part 11, including audit trails, access controls, and attributable timestamped entries. Separately, the PRO instrument itself may need documented evidence of measurement equivalence if it was originally validated on paper and migrated to a screen, particularly when the data supports a labeling claim.

How does ePRO support patient safety?

Because responses arrive in real time, study teams can configure automated notifications that alert site staff when a participant reports something that warrants follow-up, such as a symptom crossing a predefined threshold. This shortens the gap between a participant experiencing an issue and the site becoming aware of it, which supports earlier intervention and faster adverse event reporting than a paper diary reviewed at the next scheduled visit.

What should I look for in ePRO software?

Key criteria include device flexibility across BYOD and provisioned models, direct integration with your EDC system so patient data does not require separate reconciliation, real-time alerting based on response conditions, and configurability that lets your team amend assessments without vendor change orders. Also, confirm the vendor provides validation documentation for regulatory compliance and that the platform supports the languages, literacy levels, and accessibility needs of your study population.